News & Press
FDA Approves Atezolizumab to Treat BRAF V600 Unresectable or Metastatic Melanoma
Washington, DC, July 31, 2020 – On July 30, 2020, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
This announcement came after the approval from the results of a multi-center, double-blind, placebo-controlled, randomized study of 154 patients, evaluating patients with previously untreated BRAF V600 mutation-positive metastatic or unresectable melanoma. This study compared both the safety and efficacy of atezolizumab combined with cobimetinib and vemurafenib to that of a placebo with cobimetinib and vemurafenib. The overall outcome was higher progression-free survival (PFS) for the atezolizumab combination than that of the placebo.